Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea

Journal of Pediatric and Adolescent Gynecology

Volumn 17, Issue 2, 2004, Pages 75-79

  Harel, Zeev ^a,b  

^a HASBRO CHILDREN'S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Cyclooxygenase 2 inhibitors; Dysmenorrhea

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESTROGEN; FENAMIC ACID DERIVATIVE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE; ROFECOXIB; VALDECOXIB; ZOMEPIRAC;

BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DYSMENORRHEA; GASTRITIS; GASTROINTESTINAL DISEASE; GROUPS BY AGE; HUMAN; KIDNEY DISEASE; PEPTIC ULCER; PRIORITY JOURNAL; REPRODUCTION; SCHOOL; SHORT SURVEY; TOCOLYSIS; TREATMENT OUTCOME; WORK;

EID: 1642446651     PISSN: 10833188     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpag.2004.01.002     Document Type: Article

References (40)

1. Klein J.R., Litt I.F. Epidemiology of adolescent dysmenorrhea. Pediatrics. 68:1981;661.
2. Alvin P.E., Litt I.F. Current status of etiology and management of dysmenorrhea in adolescents. Pediatrics. 70:1982;516.
3. Simopoulos A.P. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 54:1991;438.
4. Chan W.Y., Hill J.C. Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. Prostaglandins. 15:1978;365.
5. Rees M.C.P., Anderson A.B.M., Demers L.M., et al. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhea. Br J Obstet Gynaecol. 91:1984;673.
6. Lundstrom V., Green K. Endogenous levels of prostaglandin F2α and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 130:1978;640.
7. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 38:1998;97.
8. Kurumbail R.G., Stevens A.M., Gierse J.K., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 384:1996;644.
9. Belt A.R., Baldassare J.J., Molnar M., et al. The nuclear transcription factor NF-(kappa)B mediates interleukin-1 (beta)-induced expression of cyclooxygenase-2 in human myometrial cells. Am J Obstet Gynecol. 181:1999;359.
10. Perkins D.J., Kniss D.A. Tumor necrosis factor-(alpha) promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs. Prostaglandins. 54:1997;727.
11. Botting R.M. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis. 31:2000;S202.
12. Chandrasekharan N.V., Dai H., Roos K.L., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 99:2002;13926.
13. Van Voorhis B.J., Huettner P.C., Clark M.R., et al. Immunohistochemical localization of prostaglandin H synthase in the female reproductive tract and endometriosis. Am J Obstet Gynecol. 163:1990;57.
14. Kim J.J., Wang J., Bambra C., et al. Expressions of cycloocygenase-1 and -2 in the baboon endometrium during the menstrual cycle and pregnancy. Endocrinology. 140:1999;2672.
15. Lim H., Paria B.C., Das S.K., et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell. 91:1997;197.
16. Tokuyama O., Nakamura Y., Muso A., et al. Expression and distribution of cyclooxygenase-2 in human periovulatory ovary. Int J Mol Med. 8:2001;603.
17. Jones R.L., Kelly R.W., Critchley H.O.D. Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. Hum Reprod. 12:1997;1300.
18. Chan W.Y., Dawood M.Y. Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy. Adv Prostaglandin Thromboxane Res. 8:1980;1443.
19. Hanson F.W., Izu A., Henzyl M.R. Naprosyn sodium in dysmenorrhea: its influence in allowing work/school activities. Obstet Gynecol. 52:1978;583.
20. Budoff P.W. Zomepirac sodium in the treatment of primary dysmenorrhea syndrome. N Engl J Med. 307:1982;714.
21. Smith R.P., Powell J.R. Intrauterine pressure changes during dysmenorrhea therapy. Am J Obstet Gynecol. 143:1982;286.
22. Mehlisch D.R. Ketoprofen, ibuprofen, and placebo in the treatment of primary dysmenorrhea: a double-blind crossover comparison. J Clin Pharmacol. 28:1988;S29.
23. Mehlisch D.R. Double-blind crossover comparison of ketoprofen, naproxen, and placebo in patients with primary dysmenorrhea. Clin Ther. 12:1990;398.
24. Marchini M., Tozzi L., Bakshi R., et al. Comparative efficacy of diclofenac dispersible 50mg and ibuprofen 400mg in patients with dysmenorrhea: a randomized, double-blind, within-patient, placebo-controlled study. Int J Clin Pharmacol Ther. 33:1995;491.
25. Owen P.R. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Am J Obstet Gynecol. 148:1984;96.
26. Roy S. A double-blind comparison of a propionic acid derivative (ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhea. Obstet Gynecol. 62:1983;628.
27. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci. 28:1998;67.
28. Goldstein J.L., Silverstein F.E., Agrawal N.M., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 95:2000;1681.
29. Hawkey C.J. COX-2 inhibitors. Lancet. 353:1999;307.
30. JLM: Second selective COX-2 inhibitor receives marketing approval. Am J Health Syst Pharm. 56:1999;1294.
31. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 345:2001;433.
32. Yuan J.J., Yang D.C., Zhang J.Y., et al. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab Dispos. 30:2002;1013.
33. Alsalameh S., Burian M., Mahr G., et al. The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther. 17:2003;489.
34. Slattery M.M., Friel A.M., Healy D.G., et al. Uterine relaxant effects of cyclooxygenase-2 inhibitors in vitro. Obstet Gynecol. 98:(4):2001;563.
35. Dore M., Mellier G., Benchaib M., et al. In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents. BJOG. 109:2002;983.
36. Morrison B.W., Daniels S.E., Kotey P., et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol. 94:1999;504.
37. Daniels S.E., Talwalker S., Torri S., et al. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol. 100:2002;350.
38. Ota H., Igarashi S., Sasaki M., et al. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod. 16:2001;561.
39. Deguchi M., Ishiko O., Sumi T., et al. Expression of angiogenic factors in extrapelvic endometriosis. Oncol Rep. 8:2001;1317.
40. Cox D.J., Meyer R.G. Behavioral treatment parameters with primary dysmenorrhea. J Behav Med. 1:1978;297.